Company / Cash & Equivalents
Olema Pharmaceuticals, Inc. Cash & Equivalents History
FY2020-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$139.5M
FY2024
5-year range
$13.8M / $338.5M
FY2020-FY2024
Trend
+103.5%
vs FY2023
Sector context
#118 of 207
Health Care
What the data says
At $139M, Olema Pharmaceuticals, Inc.'s cash & equivalents ranks #118 of 207 in the Health Care sector. Cash & Equivalents has increased for 3 consecutive years, from $14M in FY2021 to $139M in FY2024.
Based on SEC 10-K filings.
$139M in FY2024 with a 3-year CAGR of +116.1%.
Improved from $24M to $139M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +116.1%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#118 of 207 in Health CareTop 57% of 207This company $139.5M Sector average $669.5M
▼
-79.2% below sector average
Key checks
Key Insights
- Olema Pharmaceuticals, Inc.'s cash & equivalents has grown for 3 consecutive years.
- 3-year CAGR of +116.1%, indicating consistent growth.
- In FY2024, cash & equivalents increased 103.5% year-over-year.
- Ranks #118 out of 207 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 3.74 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $139.5M | +103.5% |
| FY2023 | $68.5M | +189.2% |
| FY2022 | $23.7M | +71.6% |
| FY2021 | $13.8M | -95.9% |
| FY2020 | $338.5M | - |
| FY2019 | - | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026